WT1 and glioma: In conclusion, our study revealed that an immune signature based on HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH expression effectively predicted the prognosis of ATRX-wt glioma patients, and demonstrated that immunotherapy was effective for low-risk patients.